TrialJournal of Crohn's & colitis2025

Impact of mirikizumab treatment on fatigue in patients with moderately to severely active Crohn's disease: results from the phase 3 VIVID-1 study.

Miguel Regueiro et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.